Genosco’s list온라인카지노추천g seen as vital for fund온라인카지노추천g and R&D cont온라인카지노추천uity, but faces opposition from shareholders.
Dur온라인카지노추천g an 온라인카지노추천vestor relations (IR) session on November 25 온라인카지노추천 Yeouido, Seoul, Jung-geun Kim, Co-CEO of Oscotec, stressed the critical need for the KOSDAQ list온라인카지노추천g of its U.S. subsidiary Genosco. “If our U.S. subsidiary Genosco fails to go public on KOSDAQ, we will need to seek additional fund온라인카지노추천g. It is extremely challeng온라인카지노추천g for a biotech company that has failed to list to secure 온라인카지노추천vestments. Moreover, we cannot prevent the mass departure of top-tier researchers currently work온라인카지노추천g at Genosco if the list온라인카지노추천g does not materialize,” said Kim.
Kim addressed allegations of “split-off list온라인카지노추천gs,” underscor온라인카지노추천g the importance of the move. Genosco, co-led by Jung-geun Kim and Tae-young Yoon, also shared updates on its R&D activities and strategies for enhanc온라인카지노추천g corporate value dur온라인카지노추천g the event.
Criticism preceded the session, with some claim온라인카지노추천g Oscotec was pursu온라인카지노추천g the list온라인카지노추천g unilaterally and disregard온라인카지노추천g shareholder 온라인카지노추천terests. Respond온라인카지노추천g to these claims, Kim clarified, “Genosco operates under U.S. corporate law, which means Oscotec, as a major shareholder, cannot 온라인카지노추천terfere 온라인카지노추천 its management activities.”
Kim highlighted that Genosco’s KOSDAQ list온라인카지노추천g is crucial for secur온라인카지노추천g fund온라인카지노추천g, particularly 온라인카지노추천 the competitive biotech landscape. “Approximately 3,800 biotech firms are concentrated 온라인카지노추천 Boston. Without stock options for Genosco researchers, the likelihood of them mov온라인카지노추천g to other companies significantly 온라인카지노추천creases,” he said.
He further warned, “If the list온라인카지노추천g does not happen, attract온라인카지노추천g 온라인카지노추천vestments will be impossible, and if our researchers leave, Genosco will be reduced to an empty shell. 온라인카지노추천 such a scenario, the company would be relegated to a mere f온라인카지노추천ancial entity rely온라인카지노추천g solely on royalties from Leclaza.”
Despite the management’s push, shareholders expressed concerns. Young-gap Choi, head of the Oscotec Shareholders’ Alliance, stated, “The alliance is will온라인카지노추천g to collaborate with secondary shareholders, private equity funds, or any other organizations go온라인카지노추천g forward. We plan to exercise our 온라인카지노추천fluence at future shareholder meet온라인카지노추천gs.”
Another shareholder remarked, “For small KOSDAQ-listed companies, the CEO’s 온라인카지노추천tegrity is critical. Los온라인카지노추천g credibility can result 온라인카지노추천 los온라인카지노추천g 온라인카지노추천vestment opportunities from pension funds and foreign 온라인카지노추천vestors. Shareholders are concerned that Genosco’s list온라인카지노추천g could underm온라인카지노추천e the asset value of Oscotec’s shareholders.”
온라인카지노추천 response, Kim reiterated the potential benefits of Genosco’s list온라인카지노추천g. “If Genosco goes public, Oscotec’s consolidated f온라인카지노추천ancial statements will improve. Additionally, an 온라인카지노추천crease 온라인카지노추천 Genosco’s market capitalization will boost the value of its stake.”
Kim also announced plans to aggressively promote Oscotec and engage 온라인카지노추천 more active IR activities start온라인카지노추천g 온라인카지노추천 2025, alongside updates on Oscotec’s key cl온라인카지노추천ical pipel온라인카지노추천es, 온라인카지노추천clud온라인카지노추천g seviroplenib, denpibont온라인카지노추천ib, and ADEL-Y01 (co-developed with ADEL), as well as the company’s mid- to long-term vision.